Manufacturer of Controlled Substances; Notice of Application, 19598-19599 [E9-9799]
Download as PDF
<![CDATA[
19598
Federal Register / Vol. 74, No. 81 / Wednesday, April 29, 2009 / Notices
Drug
Schedule
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
II
II
II
The company plans to manufacture
the listed controlled substances as bulk
controlled substance intermediates for
distribution to its customers for further
manufacture or to manufacture
pharmaceutical dosage forms.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such substances
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 29, 2009.
Dated: April 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–9803 Filed 4–28–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on February 11, 2009,
Siemens Healthcare Diagnostics Inc.,
Attn: RA, 100 GBC Drive, Mail Stop 514,
Newark, Delaware 19702, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
Drug
Schedule
pwalker on PROD1PC71 with NOTICES
Tetrahydrocannabinols (7370) .....
Ecgonine (9180) ...........................
Morphine (9300) ...........................
I
II
II
The company plans to produce the
listed controlled substances in bulk to
be used in the manufacture of reagents
and drug calibrator/controls which are
DEA exempt products.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
VerDate Nov<24>2008
17:48 Apr 28, 2009
Jkt 217001
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 29, 2009.
Dated: April 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–9802 Filed 4–28–09; 8:45 am]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on February 2, 2009,
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
Drug
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on January 6, 2009,
Archimica, Inc., 2460 W. Bennett Street,
Springfield, Missouri 65807–1229, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Lisdexamfetamine (1205), a basic class
of controlled substance listed in
schedule II.
The company plans to manufacture
the listed controlled substance in bulk
for distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 29, 2009.
Dated: April 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–9801 Filed 4–28–09; 8:45 am]
Frm 00114
Fmt 4703
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 29, 2009.
Dated: April 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–9800 Filed 4–28–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 11, 2009,
AMRI Rensselaer, Inc., 33 Riverside
BILLING CODE 4410–09–P
PO 00000
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Phenylacetone (8501) ..................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
Schedule
Sfmt 4703
E:\FR\FM\29APN1.SGM
29APN1
Federal Register / Vol. 74, No. 81 / Wednesday, April 29, 2009 / Notices
Avenue, Rensselaer, New York 12144,
made application by renewal to the
Drug Enforcement Administration
(DEA) as a bulk manufacturer of the
basic classes of controlled substances
listed in schedules I and II:
Drug
Schedule
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Dextropropoxyphene, bulk (nondosage form) (9273).
Oxymorphone (9652) ...................
Fentanyl (9801) ............................
I
I
II
II
II
II
II
II
II
II
II
The company plans to manufacture
bulk controlled substances for use in
product development and for
distribution to its customers.
In reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
intermediate. This controlled substance
will be further synthesized to bulk
manufacture a synthetic THC (7370). No
other activity for this drug code is
authorized for this registration.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 29, 2009.
Dated: April 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–9799 Filed 4–28–09; 8:45 am]
be registered as a bulk manufacturer of
Methamphetamine (1105), a basic class
of controlled substance listed in
schedule II.
The company plans to manufacture
bulk controlled substances for use in
product development and for
distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such a substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 29, 2009.
Dated: April 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–9804 Filed 4–28–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on February 20, 2009,
Stepan Company, Natural Products
Dept., 100 W. Hunter Avenue,
Maywood, New Jersey 07607, made
application by renewal to the Drug
Enforcement Administration (DEA) as a
bulk manufacturer of the basic classes of
controlled substances listed in schedule
II:
Drug
Schedule
Cocaine (9041) .............................
Benzoylecgonine (9180) ...............
II
II
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
pwalker on PROD1PC71 with NOTICES
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 22, 2008,
Norac Inc., 405 S. Motor Avenue, P.O.
Box 577, Azusa, California 91702–3232,
made application by letter to the Drug
Enforcement Administration (DEA) to
VerDate Nov<24>2008
17:48 Apr 28, 2009
Jkt 217001
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
PO 00000
Frm 00115
Fmt 4703
Sfmt 4703
19599
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 29, 2009.
Dated: April 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–9807 Filed 4–28–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Bob’s Pharmacy and Diabetic
Supplies; Revocation of Registration
On August 15, 2008, I, the Deputy
Administrator of the Drug Enforcement
Administration, issued an Order to
Show Cause and Immediate Suspension
of Registration to Bob’s Pharmacy and
Diabetic Supplies (Respondent), of
Winter Haven, Florida. The Show Cause
Order proposed the revocation of
Respondent’s DEA Certificate of
Registration, FB0181216, as a retail
pharmacy, and the denial of any
pending application to renew or modify
its registration, on the ground that
Respondent has committed acts which
render its ‘‘continued registration
inconsistent with the public interest.’’
Show Cause Order at 1 (citing 21 U.S.C.
824(a)(4)).
The Show Cause Order alleged that
Respondent was ‘‘knowingly engaging
in a scheme to distribute controlled
substances based on * * * prescriptions
that [were] issued for other than
legitimate medical purpose and by
physicians acting outside [of] the usual
course of professional practice, in
violation of * * * Federal and State
law.’’ Id. (citing 21 CFR 1306.04; United
Prescriptions Servs., Inc., 72 FR 50397
(2007)). More specifically, the Show
Cause Order alleged that Respondent
was ‘‘dispensing controlled substances
into states in which it is not licensed to
do so,’’ and that it was ‘‘aiding
physicians in the unauthorized practice
of medicine in those states that require
physicians to be licensed by the state
before prescribing controlled substances
to state residents.’’ Id. at 2 (citing
United, 72 FR 50407–08). The Show
Cause Order also alleged that
Respondent had ‘‘dispensed large
quantities of controlled substances
based on prescriptions purportedly
written by Sheila Soman, M.D., a
physician who was not authorized by
DEA to prescribe controlled
substances.’’ Id. Based on the above, I
further found that there was a
‘‘substantial likelihood that [Respondent
E:\FR\FM\29APN1.SGM
29APN1
]]>Agencies
[Federal Register Volume 74, Number 81 (Wednesday, April 29, 2009)]
[Notices]
[Pages 19598-19599]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-9799]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on March 11, 2009, AMRI
Rensselaer, Inc., 33 Riverside
[[Page 19599]]
Avenue, Rensselaer, New York 12144, made application by renewal to the
Drug Enforcement Administration (DEA) as a bulk manufacturer of the
basic classes of controlled substances listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Marihuana (7360)........................... I
Tetrahydrocannabinols (7370)............... I
Amphetamine (1100)......................... II
Lisdexamfetamine (1205).................... II
Methylphenidate (1724)..................... II
Pentobarbital (2270)....................... II
Hydrocodone (9193)......................... II
Meperidine (9230).......................... II
Dextropropoxyphene, bulk (non-dosage form) II
(9273).
Oxymorphone (9652)......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture bulk controlled substances for use
in product development and for distribution to its customers.
In reference to drug code 7360 (Marihuana), the company plans to
bulk manufacture cannabidiol as a synthetic intermediate. This
controlled substance will be further synthesized to bulk manufacture a
synthetic THC (7370). No other activity for this drug code is
authorized for this registration.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than June 29, 2009.
Dated: April 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-9799 Filed 4-28-09; 8:45 am]
BILLING CODE 4410-09-P
